Journal
BLOOD REVIEWS
Volume 36, Issue -, Pages 10-22Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2019.03.004
Keywords
Acquired Glanzmann thrombasthenia; Antibodies to alpha IIb beta 3; Primary and secondary immune thrombocytopenia; Leukemia and cancer; Infections and inflammation; Drug-dependent antibodies; Anti-thrombotic therapy
Categories
Ask authors/readers for more resources
In contrast to the inherited platelet disorder given by mutations in the ITGA2B and ITGB3 genes, mucocutaneous bleeding from a spontaneous inhibition of normally expressed alpha IIb beta 3 characterizes acquired Glanzmann thrombasthenia (GT). Classically, it is associated with autoantibodies or paraproteins that block platelet aggregation without causing a fall in platelet count. However, inhibitory antibodies to alpha IIb beta 3 are widely associated with primary immune thrombocytopenia (ITP), occur in secondary ITP associated with leukemia and related disorders, solid cancers and myeloma, other autoimmune diseases, following organ transplantation while cytoplasmic dysregulation of alpha IIb beta 3 function features in myeloproliferative and myelodysplastic syndromes. Antibodies to alpha IIb beta 3 occur during viral and bacterial infections, while drug-dependent antibodies reacting with alpha IIb beta 3 are a special case. Direct induction of acquired GT is a feature of therapies that block platelets in coronary artery disease. This review looks at these conditions, emphasizing molecular mechanisms, therapy, patient management and future directions for research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available